Eisai's NTD Drug Receives WHO Prequalification
News: Japan-based Eisai 's diethylcarbamazine citrate (DEC) 100mg tablets have been granted a pre-qualification from the World Health Organization (WHO), according to a company press release. The DEC has gained the pre-qualification as a treatment for lymphatic filariasis, a neglected tropical disease (NTD). Eisai is a signatory member of the London Declaration, a global public-private partnership that aims to eliminate ten NTDs by 2020. As part of its commitment to the declaration Eisai will produce 2.2bn high-quality DEC tablets at its Vizag plant in India.